Ebola Vaccines

 11.4.26

The World Health Organization (WHO) has recommended adding two new candidate vaccines—to clinical trials to fight the Bundibugyo strain of the Ebola virus.


ChAdOx1 BDBV

Oxford-developed vaccine recommended to enter pivotal trial against deadly Bundibugyo virus

“Every week this outbreak continues, more families and communities in the DRC are devastated, and the need for a vaccine against Bundibugyo virus grows more urgent. Thanks to the commitment of our partners at the University of Oxford and the Serum Institute of India, this promising candidate went from concept to clinical trials in a matter of weeks. Its recommendation for inclusion in the Tumaini study is an important step towards a BDBV-specific vaccine that can protect those most at risk.”

CEPI is funding the development of the ChAdOx1 BDBV vaccine candidate and is providing funding, scientific expertise and operational support to the Tumaini trial.

Approximately 620,000 doses of the ChAdOx1 BDBV vaccine candidate have been manufactured by the Serum Institute of India.

Moderna's mRNA-1469

mRNA-1469 is an investigational messenger RNA vaccine candidate developed by Moderna to prevent Ebola virus disease caused by the Bundibugyo ebolavirus strain (BDBV).

Current Status & Recent Updates

• Phase 2/3 Advancement: A World Health Organization (WHO) independent expert group recommended that mRNA-1469 advance into a Phase 2/3 efficacy trial in the Democratic Republic of the Congo (DRC). 

• The Tumaini Study: Subject to local regulatory approvals, the vaccine will be evaluated in the DRC as part of the ongoing "Tumaini" trial. This study uses a randomized, ring-vaccination approach to protect contacts of confirmed Ebola cases.

• Phase 1 Trial Background: The vaccine entered human clinical trials, backed by funding from the Coalition for Epidemic Preparedness Innovations (CEPI). The Phase 1 safety and tolerability study was conducted across three sites in Canada. Interim data showed it was generally well-tolerated. 

Medical Significance

While highly effective vaccines exist for the Zaire strain of Ebola (such as Merck's Ervebo), there are currently no approved vaccines or treatments targeting the Bundibugyo strain. The Bundibugyo virus has a historically high case fatality rate of approximately 40% to 44%, making mRNA-1469 a critical tool for outbreak preparedness and response.

If clinical trials prove successful, Moderna has committed to providing a minimum of 500,000 doses at accessible pricing to low- and middle-income countries. 

Comments

Post a Comment

Popular posts from this blog

Quality of Life

Image
Quality of life (QOL) is subjective and defined differently by everyone, but generally, "no quality of life" refers to a state where an individual's suffering or limitations outweigh their ability to experience joy, meaning, or basic comfort.  Physical and Functional Limitations Loss of Independence: The inability to perform basic Activities of Daily Living (ADLs), such as dressing, showering, or eating without assistance. Chronic, Unmanageable Pain: Persistent physical suffering that cannot be adequately controlled by medication or treatment, often interfering with sleep and mobility. Severe Symptom Burden: Dealing with constant, distressing symptoms like frequent nosebleeds, coughing up blood, or severe nausea that dominate daily existence. *** No quality of life" is a subjective, often terminal, state characterized by an inability to experience pleasure, profound loss of autonomy, or overwhelming pain. It is generally marked by the absence of joy, independence, an...
Read more

Another bullshit remark; calling me Sweetheart

Image
Here's what it means, because never have so many people called me sweetheart like this year. Sweetheart aka  Diabetic cardiomyopathy (DCM) is a chronic, often asymptomatic disorder of the heart muscle in diabetics (type 1 or 2) that causes structural damage and functional impairment, leading to heart failure independently of coronary disease or hypertension. It presents as early diastolic dysfunction (stiffness) progressing to systolic failure. Systolic failure: Systolic heart failure, or  heart failure with reduced ejection fraction  (HFrEF),  occurs when the left ventricle becomes weak or enlarged and cannot contract properly to pump sufficient blood to the body This condition leads to fluid buildup in the lungs and body, causing fatigue, swelling, and breathing difficulties.
Read more